Literature DB >> 15500950

RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line.

Mercedes M Leon-Blanco1, Juan M Guerrero, Russel J Reiter, David Pozo.   

Abstract

The RNA expression levels of human catalytic subunit (TERT) and the RNA subunit (TR) of telomerase were analysed after treatment with the agonists of the membrane receptor (S 20098) and the nuclear receptor (CGP 52608) for melatonin in the MCF-7 human breast tumor cell line. Neither membrane nor nuclear signalling affected the RNA steady-state levels of the TR subunit of telomerase. On the contrary, we observed a significant decreased in the RNA levels of TERT after treatment with CGP 52608 while S 20098 produced a significant increase in the RNA levels of TERT. These results support a cross-talk between membrane and nuclear melatonin signalling and provide new data on the hormonal regulation of telomerase function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15500950     DOI: 10.1016/j.canlet.2004.05.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 3.  Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night.

Authors:  David E Blask; Steven M Hill; Robert T Dauchy; Shulin Xiang; Lin Yuan; Tamika Duplessis; Lulu Mao; Erin Dauchy; Leonard A Sauer
Journal:  J Pineal Res       Date:  2011-05-24       Impact factor: 13.007

4.  Violet and blue light blocking intraocular lenses: photoprotection versus photoreception.

Authors:  M A Mainster
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

5.  Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells.

Authors:  Jiaojiao Hao; Zhenglin Li; Changlin Zhang; Wendan Yu; Zhipeng Tang; Yixin Li; Xu Feng; Yue Gao; Quentin Liu; Wenlin Huang; Wei Guo; Wuguo Deng
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

Review 6.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 7.  Melatonin Therapy in Patients with Alzheimer's Disease.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Luis I Brusco
Journal:  Antioxidants (Basel)       Date:  2014-04-10

Review 8.  Implications of telomeres and telomerase in endometrial pathology.

Authors:  D K Hapangama; A Kamal; G Saretzki
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

Review 9.  Melatonin and Cancer Hallmarks.

Authors:  Wamidh H Talib
Journal:  Molecules       Date:  2018-02-26       Impact factor: 4.411

10.  Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.

Authors:  Jiaojiao Hao; Wenhua Fan; Yizhuo Li; Ranran Tang; Chunfang Tian; Qian Yang; Tianhua Zhu; Chaoliang Diao; Sheng Hu; Manyu Chen; Ping Guo; Qian Long; Changlin Zhang; Ge Qin; Wendan Yu; Miao Chen; Liren Li; Lijun Qin; Jingshu Wang; Xiuping Zhang; Yandong Ren; Penghui Zhou; Lijuan Zou; Kui Jiang; Wei Guo; Wuguo Deng
Journal:  J Exp Clin Cancer Res       Date:  2019-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.